Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201 [Yahoo! Finance]
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial [Yahoo! Finance]
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, down previously from $7.00.
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $8.00 price target on the stock, down previously from $10.00.